Delivery of antitumor compounds to the rat colon: In vitro and in vivo evaluation

被引:17
作者
Ciftci, K
Groves, MJ
机构
[1] UNIV ILLINOIS,COLL PHARM,INST TB RES,CHICAGO,IL 60607
[2] UNIV MICHIGAN,MED SCH R5014,ANN ARBOR,MI 48109
关键词
5-FU; hydroxypropylmethylcellulose; Eudragit(TM); colonic drug delivery; rat; GI transit;
D O I
10.1016/S0378-5173(96)04764-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Using a rat model we have demonstrated that an enteric-coated hydroxypropyl-methylcellulose (HPMC) granular formulation was capable of targeting or persisting in the colonic region. The formulation was optimized by measuring the in vitro release of 5-fluorouracil (5-FU) of granules prepared with different molecular weights of HPMC ('Methocel') coated with different hydrophobicities of acrylic acid copolymers ('Eudragits'), a 'Methocel' K100M granule coated with 'Eudragit'-S being selected. X-ray examination of lightly anaesthetized rats demonstrated that orally administered enteric-coated granules containing 50% w/w barium sulfate persisted in the colon for longer than similar barium sulfate suspensions. Granules of HPMC, coated and uncoated, containing 5-FU were administered by oral gavage and the tissue levels of drug were determined by high performance liquid chromatography. At 6 h, drug from the uncoated formulation could be found in all tissues examined. On the other hand, at 8 h, drug from the coated granules could only be found in significant quantities in colon contents and colon tissue homogenates with increasing amounts being measured at 12 and 24 h. These data suggest that, at least in the rat model, formulations can be designed that would persist in the colon and rectal regions, releasing drug to and not through the tissues. This concept might be valuable in the post-surgical treatment of colonic cancer, reducing the required dose of drug and therefore side effects. This should improve patient compliance and thus, the treatment outcome. Copyright (C) 1996 Elsevier Science B.V.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 26 条
[1]   ANALYSIS OF 5-FLUOROURACIL IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BARBERIHEYOB, M ;
MERLIN, JL ;
WEBER, B .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 581 (02) :281-286
[2]  
BECK LR, 1979, FERTIL STERIL, V31, P545
[3]   PRODRUGS OF 5-FLUOROURACIL .3. HYDROLYSIS KINETICS IN AQUEOUS-SOLUTION AND BIOLOGICAL MEDIA, LIPOPHILICITY AND SOLUBILITY OF VARIOUS 1-CARBAMOYL DERIVATIVES OF 5-FLUOROURACIL [J].
BUUR, A ;
BUNDGAARD, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 23 (02) :209-222
[4]   PRODRUGS OF 5-FLUOROURACIL .8. IMPROVED RECTAL AND ORAL DELIVERY OF 5-FLUOROURACIL VIA VARIOUS PRODRUGS - STRUCTURE RECTAL ABSORPTION RELATIONSHIPS [J].
BUUR, A ;
BUNDGAARD, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 36 (01) :41-49
[5]   MICROSPHERES OF 5-FLUOROURACIL USING POLY(DL-LACTIC ACID) - IN-VITRO RELEASE PROPERTIES AND DISTRIBUTION IN MICE AFTER IV ADMINISTRATION [J].
CIFTCI, K ;
HINCAL, AA ;
KAS, HS ;
ERCAN, MT ;
RUACAN, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 1 (05) :249-258
[6]   NON-LINEAR PHARMACOKINETIC MODELS FOR 5-FLUOROURACIL IN MAN - INTRAVENOUS AND INTRAPERITONEAL ROUTES [J].
COLLINS, JM ;
DEDRICK, RL ;
KING, FG ;
SPEYER, JL ;
MYERS, CE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (02) :235-246
[7]   RESPONSE OF PRIMARY COLON-CANCER CELLS IN HYBRID SPHEROIDS TO 5-FLUOROURACIL [J].
DJORDJEVIC, B ;
LANGE, CS ;
ALLISON, RR ;
ROTMAN, M .
CANCER INVESTIGATION, 1993, 11 (03) :291-298
[8]  
EBEL JP, 1994, PHARMACEUT RES, V10, P233
[9]   MUCOUS SECRETION IN RAT COLONIC MUCOSA DURING CARCINOGENESIS INDUCED BY DIMETHYLHYDRAZINE - MORPHOLOGICAL AND HISTOCHEMICAL STUDY [J].
FILIPE, MI .
BRITISH JOURNAL OF CANCER, 1975, 32 (01) :60-77
[10]  
FINAN PJ, 1987, EUR J SURG ONCOL, V13, P349